Or perhaps a compound similar to Copaxone appears to have benefits in controlling the disease as well as actual Copaxone with allegedly no major difference in side effects.
This could be interpreted as positive for MNTA as its compound may more closely conform to Copaxone via better characterization techniques and any doubters at the FDA might be able to infer and embrace that MNTA's compound will have similar benefits and side effects.
Market Data 
Markets 
AI
